A director at Apellis Pharmaceuticals Inc sold after exercising options/sold 139,365 shares at 20.185USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 30 - August 2 in Long Beach, California. These data further demonstrate the robust efficacy and well-documented safety profile of SYFOVRE® (pegcetacoplan injection) for patients with geograp...
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGNNon-dilutive financing further strengthens Apellis’ balance sheet Apellis retains full U.S. commercialization rights for systemic pegcetacoplanTransaction underscores shared confidence in the meaningful growth potential in rare kidney diseases WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq...
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients No new safety signals were observedNew data presented at late-breaking session at the European Renal Association CongressMarketing applications for EMPAVELI are under review with the FDA and EMA WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new dat...
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis...
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGNOn track to initiate two pivotal tri...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.